Recent developments include quarterly earnings transcripts, regulatory updates on DrugSorb-ATR, and analyst recommendations.

• Cytosorbents released its Q4 2025 earnings transcript detailing financial and operational results [N1].
• D. Boral Capital maintained a Buy recommendation on Cytosorbents in December 2025 [N2].
• HC Wainwright & Co. maintained a Neutral recommendation on Cytosorbents in November 2025 [N3].
• D. Boral Capital also maintained a Buy recommendation in November 2025 [N4].
• The company issued a regulatory update on DrugSorb-ATR in September 2025, announcing plans to file a new De Novo application with additional data [N6].
• Earlier in July 2025, Cytosorbents provided a regulatory update on DrugSorb-ATR [N7].
• The company reported Q3 2025 earnings in November 2025 [N5].
• Cytosorbents reported quarterly earnings results in May 2025 [N8].

Cytosorbents’ technology addresses significant unmet medical needs in critical care and cardiac surgery by potentially improving outcomes in life-threatening conditions involving severe inflammation and bleeding risks. Its global distribution network and multiple product lines provide diversified revenue streams. The company’s ongoing regulatory efforts for DrugSorb-ATR, including plans to submit a new De Novo application with additional real-world data, could enhance its U.S. and Canadian market opportunities. Strategic partnerships with established medical device companies support commercialization and market penetration. The company’s proprietary technology and intellectual property provide a foundation for future innovation and product development.

Cytosorbents faces significant regulatory risks, including FDA denial of its initial DrugSorb-ATR De Novo request and Health Canada refusal, which delay or limit market access in key regions. Market acceptance of its products is uncertain and depends on clinical validation, reimbursement, and competitive dynamics. The company’s stock price is below Nasdaq’s minimum bid price requirement, risking delisting and reduced liquidity. Financial losses and limited cash reserves may constrain operational flexibility. Competition from alternative blood purification technologies and potential challenges in scaling commercialization could impact growth prospects.

Cytosorbents’ moat is based on its proprietary polymer bead technology that enables selective removal of harmful substances from blood without the use of ligands or biologics. This technology underpins multiple approved and commercialized products with applications in critical care, cardiac surgery, organ transplantation, and veterinary medicine. The company’s established global distribution and co-marketing partnerships provide market reach and support. Its intellectual property portfolio, including patents and exclusive licenses, protects its technology. However, the moat is challenged by regulatory hurdles, the need for clinical validation, and competition from alternative blood purification technologies.

• Regulatory Approval Risks: The company has faced FDA denial and Health Canada refusal for DrugSorb-ATR, requiring additional data and resubmission, which may delay or prevent market authorization.
• Market Acceptance Risks: Even with regulatory approvals, the company’s products may not achieve sufficient adoption due to clinical, reimbursement, or competitive factors.
• Nasdaq Listing Compliance Risk: The company’s stock price is below the minimum bid price requirement, with a cure period ending March 31, 2026, risking delisting and reduced stock liquidity.
• Financial Risks: The company reported a net loss of $8.2 million in 2025 and holds limited cash reserves, which may impact its ability to fund operations and growth.

• Cytosorbents Corp is a medical technology company focused on blood purification to treat life-threatening conditions in intensive care and cardiac surgery using proprietary polymer bead technology.
• The company commercializes several products including CytoSorb (approved in the EU and distributed in over 70 countries), ECOS-300CY (for ex vivo organ perfusion), VetResQ (for veterinary critical care), and the PuriFi hemoperfusion pump in select international markets.
• CytoSorb removes harmful substances such as cytokines, bilirubin, and myoglobin from blood to reduce inflammation and organ failure risks in critical illnesses like sepsis, COVID, trauma, and liver failure.
• The company is seeking FDA and Health Canada approval for DrugSorb-ATR, a device to reduce perioperative bleeding in patients on blood thinners undergoing cardiac surgery.
• FDA denied the initial De Novo request for DrugSorb-ATR in April 2025 due to insufficient data supporting the desired label indication, but found no safety issues; the company filed an appeal and participated in supervisory review.
• The FDA upheld the denial in August 2025 but proposed a potential expedited path forward; the company decided not to pursue a final appeal and plans to file a new De Novo application with additional real-world data in early 2026.
• Health Canada refused the Medical Device License application for DrugSorb-ATR in June 2025; the company withdrew its request for reconsideration to await FDA clarity and plans to resubmit later.
• The company has multiple distribution and co-marketing agreements globally, including with Fresenius Medical Care AG, Aferetica s.r.l. in Italy, Terumo Cardiovascular Group in France, and B. Braun Avitum AG for critical care platforms outside the US.
• Royalty agreements exist related to the company's technology, including a 3% royalty on sales of CytoSorb and related products; the term of a prior license agreement expired in August 2024 with no further payments.
• Financial snapshot as of December 31, 2025: cash and equivalents of $6.25 million, current assets of $20.63 million, current liabilities of $9.71 million, current ratio of 2.13, and cash ratio of 0.64.
• For fiscal year 2025, the company reported a net loss of $8.2 million and basic and diluted EPS of -$0.13 per share.
• The company’s common stock trades on Nasdaq under ticker CTSO, with a market price of $0.567 as of March 30, 2026, and approximately 62.7 million shares outstanding as of March 20, 2026.
• The company was notified in October 2025 of non-compliance with Nasdaq’s minimum bid price requirement (below $1.00) and has a cure period until March 31, 2026, to regain compliance to avoid delisting.
• Market acceptance of the company’s products depends on regulatory approvals, demonstration of safety and efficacy, reimbursement policies, competition, and marketing effectiveness.
• The company faces risks related to regulatory approvals, market acceptance, and Nasdaq listing compliance.
• Recent news includes multiple earnings transcripts and regulatory updates, including plans to file a new De Novo application for DrugSorb-ATR in early 2026.
• The company reported strong Q4 2024 results and continues to engage with FDA and Health Canada on regulatory pathways for DrugSorb-ATR.